Sino Biopharmaceutical Limited (SBMFF)
OTCMKTS · Delayed Price · Currency is USD
0.9162
+0.0353 (4.01%)
At close: Jul 18, 2025

Sino Biopharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
15,7257,5008,17310,83213,13318,176
Upgrade
Market Cap Growth
-6.32%-8.23%-24.55%-17.52%-27.74%3.57%
Upgrade
Enterprise Value
16,4998,2998,49811,56414,63618,844
Upgrade
Last Close Price
0.920.410.400.570.650.95
Upgrade
PE Ratio
32.8015.6424.8529.375.7142.82
Upgrade
PS Ratio
3.981.902.212.873.115.02
Upgrade
PB Ratio
2.681.281.521.972.215.29
Upgrade
P/TBV Ratio
3.731.781.962.592.847.22
Upgrade
P/FCF Ratio
20.309.6811.6014.8822.8430.42
Upgrade
P/OCF Ratio
17.358.289.5511.9315.5522.28
Upgrade
EV/Sales Ratio
4.212.102.303.073.465.20
Upgrade
EV/EBITDA Ratio
17.748.799.4512.7517.0521.73
Upgrade
EV/EBIT Ratio
21.4110.4411.0814.8120.0730.02
Upgrade
EV/FCF Ratio
21.3010.7112.0615.8825.4631.54
Upgrade
Debt / Equity Ratio
0.230.230.330.370.330.63
Upgrade
Debt / EBITDA Ratio
1.391.391.972.222.212.48
Upgrade
Debt / FCF Ratio
1.721.722.542.813.363.64
Upgrade
Asset Turnover
0.450.450.410.420.500.56
Upgrade
Inventory Turnover
2.442.442.312.102.792.93
Upgrade
Quick Ratio
1.111.110.901.151.381.87
Upgrade
Current Ratio
1.261.261.051.291.532.08
Upgrade
Return on Equity (ROE)
11.82%11.82%12.12%11.94%55.25%20.20%
Upgrade
Return on Assets (ROA)
5.62%5.62%5.33%5.40%5.37%6.05%
Upgrade
Return on Capital (ROIC)
7.02%7.02%6.60%6.60%6.69%7.79%
Upgrade
Return on Capital Employed (ROCE)
12.70%12.70%13.30%12.30%10.30%11.30%
Upgrade
Earnings Yield
3.05%6.39%4.02%3.40%17.51%2.33%
Upgrade
FCF Yield
4.93%10.33%8.62%6.72%4.38%3.29%
Upgrade
Dividend Yield
0.56%2.19%1.55%2.71%1.59%0.99%
Upgrade
Payout Ratio
19.45%52.76%27.13%49.84%6.42%42.84%
Upgrade
Buyback Yield / Dilution
2.36%1.26%2.57%1.38%-2.57%0.06%
Upgrade
Total Shareholder Return
3.08%3.45%4.12%4.08%-0.98%1.05%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.